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Preliminary retrospective studies of tissue typing in man were based upon 
comparison of lymphocyte antigens of chronic survivors with their donors 
after renal homotransplantation.1~3 In  the last report3 a statistically signifi- 
cant association was demonstrated between the excellence of the late clinical 
outcome and the donor-recipient compatibilities in the leukocyte groups tested. 
These initial efforts to establish the relationship between the antigens under 
analysis and human histocompatibility factors were not altogether satisfacto- 
ry, however, since they involved solely retrospective observations on patients 
long after operation. These studies of surviving recipients and their donors 
excluded the early failures from consideration. Furthermore, although a corre- 
lation existed in the chronic survivors between the excellence of antigenic 
match and the benignancy of their course, several patients with mediocre 
matches had achieved good long-term results. Conversely, some patients with 
apparently good matches had developed late problems.2 
Nevertheless, the results were sufficiently encouraging to warrant a trial of 
prospective matching. This has been carried out in 32 patients treated from 
Octoberl2,1964 to October 12,1965. In  each instance, the donors were selected 
in Los Angeles on the basis of the best available match, either from a related 
or nonrelated population. Transplantation was subsequently carried out either 
a t  the Colorado General Hospital or the Denver Veterans Administration Hos- 
pital. The collaboration provided certain advantages for evaluation of the 
results. First, the surgical and medical practices in the Denver institutions 
*Aided by grants AM02375, AI04444, AM7513, AM06283, AM06344, HE07735, 
AM07772, AI04152, FR00051, FR00069, and FR3 from the United States Public 
Health Service, a grant from the California Cancer Research Coordinating Committee 
and a grant from the Medical Research Council of Great Britain. Computational assis- 
tance was obtained from U.C.L.A. Health Sciences Computer Facility. 
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were relatively well standardized. In addition, the results obtained with 64 
4 previous cases in which the donor and recipient were randomly selected were 
available for comparison. Finally, all available pathologic material in the 
original unselected series had been examined by K. A. Porter, making possible 
a histopathologic correlation between the failures in the original nonselected 
group and those of the present studies. 
Subjects 
Thirty-two consecutive cases are included. An additional patient who ulti- 
mately received a nonselected cadaveric kidney because of initial technical 
failures is excluded. The donor-recipient ABO groups were all compatible by 
previously defined   rite ria.^ 
Eighteen of the recipients received their homografts from blood relatives 
(TABLE 1); ten from parents, seven from siblings, and one from an uncle. In  
ten cases, only one donor was available. In the other eight, the choice was 
made between two or more donors. 
The other 14 recipients had their homografts provided by unrelated volun- 
teer donors (TABLE 2). These donors were members of a pool which was com- 
prised of 108 members a t  its maximum.** The largest number of available 
volunteers in each ABO blood group was 51 type 0 ,  46 type A, 7 type B, and 
4 type AB. In  practice, since the pool varied in composition, selection was 
generally made from about half of the above total. 
Therapy 
Whenever possible, azathioprine was administered starting several days in 
advance of homotransplantation and continued indefinitely after operation. 
Prednisone was initiated on the day of operation in doses of 30-200 mg; in the 
event of rejection, the dose was increased. Actinomycin C and local homo- 
graft irradiation were employed only a t  the time of diagnosed rejection. All 
patients had splenectomy and all but one had bilateral nephrectomy a t  the 
time of transplantation. 
Thymectomy was carried out prior to transplantation on randomly se- 
lected patients in 17 of the 32 cases. In past experience, thymectomy has not 
had a demonstrable effect on the early course after human t r a n ~ ~ l a n t a t i o n ~ ' ~ ;  
furthermore, in the time interval of the present series, thymectomy has not 
appeared to influence survival. Consequently, all results in the present series 
are pooled without further consideration of thymectomy. 
**Penal volunteers. 
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TABLE 1 
DATA ON PATIENTS WHO RECEIVED HOMOGRAFTS FROM BLOOD RELATIVES 
Date of Blood # Sera Mismatch Donor 
LD # Age-Sex Transplant Groups Tested % Sera Groups Relation 
--- 
R D 
65  35 - F 10-12-64 0 +  G+ 89 1.1 0 Sister 
66 29 - M 10-26-64 0 +  O+ 91 1.1 0 Mother 
68 24 - F 12- 2-64 0 +  O+ 113 1.8 0 Sister 
73 27 - M 2- 1-65 A+ A+ 120 10.0 2 Sister 
75 18 - M 2-19-65 A+ A+ 106 9.4 1 Father 
3-6t, 5 
76 27 - M 3-12-65 A- A- 99 14.1 2 Brother 
79 16 - M 3-23-65 A+ A+ 128 10.9 1, x$ Mother 
-- 
8 1  19 - M 3-30-65 0 +  0 +  123 11.4 2, 1, x Father 
83 21 - F 4- 9-65 A+ A+ 111 2.7 0 Brother 
84 20 - F 4-12-65 A+ O+ 109 15.6 2 Sister 
85  18 - M 4-23-65 0 +  O+ 124 9.7 x Sister 
89 2 3 - M  6-15-65 0 +  O+ 129 0.8 0 Father 
3, 1 
90 18 - F 7-23-65 A+ 0 +  113 11.5 x Mother 
93 8 - F 8- 6-65 A2B+ AIB- 112 2.7 0 Mother 
94 26 - F 8-24-65 A- A+ 94 13.8 2, x Father 
95 28 - M 8-30-65 0 +  0+ 107 21.5 1, 2, x Mother 
96 25 - M 9- 7-65 0 +  0- 107 15.0 5. x Father 
97 17 - M 10-12-65 0+ 0 +  94 11.7 6, 5, x Uncle 
* The donors were selected on the basis of the best possible antigenic 
match within the family. The great variation in quality of match was necessi- 
tated by the limited number of donors in individual cases; frequently only 
one medically suitable donor was available. 
t 3-6 classification: results from a mismatch in a group of antisera which 
a re  associated with both group 3 and group 6 sera.  
$ x = 3 o r  more mismatches in the group of unclassified antisera. 
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TABLE 1, Cont. 
Date of Survival § Current Current Treatment: Thymectomy Death (Days) BUN Ccr Imuran Prednisone 
- - 16 2 26 99 175 20 
9-30-65 - 127 50 50 137.5 60 
§ To death o r  to 16 February 1966. 
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TABLE 2 
DATA ON PATIENTS WHO RECEIVED HOMOGRAFTS FROM NONRELATED 
LIVING DONORS 
Date of Blood # Sera Mismatch Thymec- 
LD # Age-Sex Transplant Groups Tested % Sera Groups tomy 
--- 
R D 
* The donors employed were selected from a pool, on the basis of the best 
possible antigenic match. 
? 3-6 classification: results from a mismatch in a group of antisera which 
a re  associated with both group 3 and group 6 sera .  
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TABLE 2, Cont. 
Date of Death Survival $ Current Current Treatment: bays  BUN Ccr Imuran Prednisone 
Removed 10 days 
- 295 25 114 100 20 
10-21-65 79 - - - - 
f To death or to 16 February 1966. 
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Serologic Testing 
Blood samples were drawn from the prospective donor and recipient into 
heparinized tubes containing small glass beads and sent by air mail, special 
delivery to Los Angeles where the lymphocytes were isolated. Antigen testing 
was performed by reacting the lymphocytes with a panel of 89 to 135 antisera. 
The technique was slightly modified from that previously described1 in that 
the results were expressed as positive or negative scores on the basis of reactiv- 
ity with :2 dilutions of each antiserum (0.003 ml and 0.001 ml). 
Mismatches were recorded whenever the donor was positive and the recipi- 
ent negative with any given antiserum. A match was considered to be present 
in all instances in which the donor's cells failed to react with any given anti- 
serum, even if the corresponding recipient cells were not tested against the 
same antiserum, and in all instances in which the recipient cells reacted with a 
given serum, even if the corresponding donor cells were not tested with that 
particular antiserum. 
The relative compatibility of any donor-recipient combination was stated 
in two ways. The first test of compatibility expressed the number of mis- 
matches as a percentage of the total mismatched antisera which were either 
measured or deduced (as described above). The second expressed the mis- 
matches as incompatibilities in one or more of six major antigenic groups into 
which the antisera had been placed on the basis of chi-square  association^.^ 
For purposes of this study, a group incompatibility was assumed to exist when 
three or more antisera within that group were mismatched. Three or more mis- 
matches with nongroupable antisera were also arbitrarily classified as a single 
group mismatch (group X). 
I t  should be noted that the above groups have recently been found to be 
associated with the following leukocyte groups described by others5: group 1: 
LA1, 7d, Dausset group 8; group 2: Dausset Mac or group 1, Shulman B1, 
LA2,8a, Amos 1; group 3: 4a, Dausset group 3; group 5: 6b, Dausset group 9, 
4d; group 6: 4c, 9a; and group 7: Dausset group 7,4b. 
Histopathologic Analysis 
Eleven patients in the present series died 5, 39, 50, 53, 79, 93, 157, 242, 
254, 295 and 314 days after operation. During this interval in the original 
series of 64 nonmatched homotransplants, 26 autopsy specimens became avail- 
able for similar analysis. 
Antigenic Matching with Related Donors 
A detailed listing of the specific incompatibilities encountered in matchings 
with the unused donors and the actually selected donors for each recipient is 
given in the right-hand half of FIGURE 1. Mismatches, indicated by the dots, 
Terasaki et al.: Serotyping for Homotransplantation 507 
FIGURE 1. Incompatibilities of individual sera in the selected series of kidney trans- 
plant recipients. The antisera are listed vertically in groups. The dots represent mis- 
matches that occurred between the donors and the recipients whose numbers are given 
across the top line. The mismatches that occurred with the actual donor used are given for 
each recipient. In instances in which related donors were also considered, the actual 
donor is denoted by "A" and the other nonselected donors, by "B", "C", etc. 
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can be rioted to occur frequently in clusters within the subdivided groups of 
antisera. Selection of the donor was based on two criteria, the lowest percent- 
age of total antisera which were mismatched and the fewest groups mismatched. 
Mismatches in group six were avoided whenever possible on the basis of earlier 
3 indications that this group may be stronger than the others. 
The pool of suitable prospective donors for any given case was, of course, 
limited, often making it necessary to proceed, despite the preseme of a signi- 
ficant number of incompatibilities. With respect to the percentage of antisera 
mismatched, the mean among the 18 related pairs was 9.56 1.43 (s.e.) as 
compared to a mean of 11.32 * 0.71 (s.e.) in 203 matchings among 66 random 
related family groups. These means are not significantly different (P = 0.3). 
With respect to groups of mismatch, the proportion of selected transplants 
with few groups of mismatch was almost like that found3 in earlier studies of 
kidney transplant recipients who had survived more than one year (FIGURE 
2), differing, however, in that a fairly high proportion of transplants with 
RELATED UNRELATED 
40 r 
( 2 0 3  matches) ( 1 1 , 1 3 0  matches) 
R A N D O M  
1 0  
0 & 
5 0  
- 2 0  LONG-TERM SURVIVORS 
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0 1 0  
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SELECTED 
1 0  
0 
Number o f  qroups m i s m a t c h e d  
FIGURE 2. Distributions of the total number of groups that mismatch. The number of 
groups that mismatch (counting the antisera which were unclassifiable as a miscellaneous 
x group), for any given pair of individuals were first totalled. The proportion of pairs 
which were mismatched in a total of O,1,2,3,  etc. groups were plotted for each category. 
Terasaki et al.: Serotyping for Homotransplantation 509 
three groups of mismatch had to be accepted. From a limited family donor 
pool, the "selection" bften consisted of ruling out extremely badly matched 
donors and donors mismatched in group six (except in LD97 and partially, in 
LD76). 
Antigenic Matching with Nonrelated Donors 
Certain observations were much clearer in the nonrelated than in the re- 
lated donor matching program. A minority of the donor pool, for example, did 
not have a good representation of the antigens being tested. Such people would 
be suitable for many recipients and might be considered to be "universal 
donors." At the other end of the spectrum there were a few volunteers whose 
lymphocytes possessed many antigens, thus making them unsuitable as donors 
for almost all the recipients. 
Conversely, patients with many antigens were "universal recipients" and 
presented no difficulty in matching. Those with few antigens created a serious 
problem. An example is shown in FIGURE 3 of the incompatibilities that oc- 
curred when 40 type 0 volunteers were considered as prospective donors for a 
type 0 patient (LD70). This patient's own mother, aunt and cousins were also 
badly mismatched (FIGURE 1, 70E, D and B,C respectively). I t  was only by 
selecting the rare donor (the first donor of FIGURE 3) that a matching was 
achieved in which low numbers of incompatibilities and no groups of mismatch 
were present. This patient is alive with good renal function 13 months after 
operation. 
In spite of the presence of the relatively large donor pool, a significant 
number of mismatches had to be accepted in many of the 14 transplanted re- 
cipients (FIGURES 1 & 2). The mean percentage of antisera mismatched at- 
tained for the 14 pairs of recipients of nonrelated kidneys was 8.04 + 1.22 
(s.e.). This was significantly less than the mean, 13.58 + 0.52 of 11,130 
matches in a random population of 106 subjects, (P = 0.001). The distribution 
of incompatibilities considered by groups was towards the favorable side 
among the selected pairs (FIGURE 2), and highly mismatched pairs appear to 
have been avoided. I t  was not possible, in every case, to select a donor with 
only one or no groups of incompatibility. 
Survival of Related Patients 
The dates of operation, current function, and immunosuppressive therapy 
are documented in TABLE 1. Two of the 18 patients died during the first 120 
days and three more died 242, 254 and 314 days after transplantation. Of the 
surviving 13 patients, six have survived 4 to 8 months; four, 8 to 12 months; 
and three, more than one year. 
In TABLE 3 these results are compared with those obtained previously,2'4 
using unmatched donors. I t  will be noted that although no trend in improve- 
ment of survival had been noted with increasing experience in the three earlier 
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FIGURE 3. Incompatibilities of individual sera found in matchings of a random pool of 
40 volunteers to one recipient (LD70). Comparison with FIGURE 1 shows that numerous 
mismatches had occurred with most of the donors to this one recipient. The first donor 
shown was chosen. 
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TABLE 3 
DEATHS IN ALL PATIENTS TREATED IN DENVER WITH HOMOGRAFTS 
FROM LIVING VOLUNTEER DONORS* 
RANDOM DONORS : 
Dates of Transplant 
-- - 
SELECTED DONORS: 
11-24-62 to 8-12-63 
Related 16 
Nonrelated 6 
No. 
8-16-63 to 12-7-63 
Related 15 
Nonrelated 7 
12-8-63 to 3-30-64 
Related 15 
Nonrelated 5 
120 days 
10-12-64 to 10-12-65 
Related 
Nonrelated 
120- 365 
days 
* For analysis of a possible trend in improvement with time, the original 
series of 64 recipients who receivedkidneys from random donors was divided 
into thirds. 
groups, there is a slight increase in early survival in the present series. This 
early improvement is also evident, if the life-survival curves of the present 
series are plotted against those of the pooled earlier series of 64 patients (FIG- 
URE 4). 
The survival data of the earlier series of 64 patients and the selected series 
of 18 related patients can be described in terms of early deaths and longer- 
term survivors. In  the unselected series, the early deaths follow a negative 
exponential distribution of survival time, with average survival of 73.5 days, 
or a half-life of 51 days. The distribution of survival time of early-death pa- 
tients was essentially the same for the nonrelated and the related groups 
(average 73 and 74 respectively). In  the present selected series of 18 patients, 
the average survival time of the five patients who died within the first year 
(TABLE 1) is 180 days. The increase in average survival is of statistical signi- 
ficance (P = 0.02). 
In the early series of 64 patients, the main difference between the related 
and nonrelated groups was the percentage of longer-term (> 12 months) survi- 
vors (related 67 per cent, nonrelated 33 per cent). This difference is statistical- 
ly significant a t  P=0.03 as obtained by chi-square. The fraction of longer- 
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FIGURE 4. Survival curve of the first Denver series (random donors) versus the Den- 
ver I1 series. The cumulative proportion of survivors was calculated by a computer pro- 
gram.6~ecause of the limited number of patients in the second selected series and the 
statistical variability of the curve, only the computed points are indicated for the second 
series. 
term survivors among the 18 selected related patients, 58 percent (as esti- 
mated from life table calculations6), does not differ materially from that of 
the earlier series. 
Severe difficulty with control of rejection was encountered in only one 
patient (I,D79). This patient had a progressive decline in renal function dur- 
ing the first several months after operation and ultimately had a creatinine 
clearance of 10-20 ml per minute, with a BUN of 40-100 mg per cent. No 
instances of renal shutdown occurred during rejection crises. 
Causes o f  Death in Related Group 
Sepsis was the direct cause of death in each of the five unsuccessfully 
treated patients: pancreatic abscesses secondary to gastric ulcer penetration 
(LD66); Pneumocystis carinii pneumonitis and Pseudomonas aeruginosa septi- 
cemia (LD76); Aspergillus fumigatus brain abscess (LD79); monilial enteroco- 
litis (LD81); and Pseudomonas aeruginosa wound infection and Pneumocystis 
carinii pneumonitis (LD83). Patient LD83 developed a ureteric fistula after 
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transplantation which could not be closed despite several reoperations; the 
ultimately fatal sequence of events thus followed a technical complication. 
Pathology of Related Homografts 
One (LD81) of the four kidneys was normal. Two (LD66 and LD83) 
showed acute tubular necrosis due to hypotension in the last few days of life. 
Changes related to rejection were encountered in the other two homografts 
(LD76 and LD79). Both showed fibrous intimal thickening of many interlobu- 
lar, arcuate and interlobar arteries and several of the vessels were completely 
occluded by this obliterative process. In some arteries, these changes were 
accompanied by reduplication of theinternal elastic lamina, whereas, in others, 
the elastic layer was ruptured. Tubular atrophy and interstitial fibrosis were 
prominent in these two homografts as a result of the ischemia. 
In TABLE 4, these pathological changes are compared with those found ir 
the 14 related renal homografts from the original nonselected series. I t  will be 
noticed that fibrinoid necrosis of arteriolar and arterial walls, a change not 
seen in the matched series, affected 43 percent of the grafts in the original 
series. This type of vascular lesion is almost invariably associated with active 
acute rejection7 and its high incidence in the series of unselected transplants 
reflects the greater number of these patients who died with unreversed rejec- 
tion. Arterial fibrous intimal thickening, a common legacy of past rejection 
episodes, also tended to be more frequent in the original series. Deposits of 
PAS-positive material on the glomerular capillary basement membranes, gen- 
erally a late manifestation of incompatibility, only occured in one t ranspla~t  
from the original unmatched series. Cellular infiltration was equally common 
in both groups of transplants; this can be a feature of acute tubular necrosis as 
well as rejection. 
Survival of Nonrelated Homografts 
Four of the 14 patients died during the first 120 days and two subse- 
quently died after 157 and 295 days. The shortest follow-up on the eight sur- 
viving patients is 6 and $ months. Four have survived 9 to 12 months and 
three, more than one year. 
The comparison of these results with those obtained previously, using non- 
selected nonrelated donors is provided in TABLE 3. In these three nonmatched 
groups done a t  different time intervals, the four-month mortality rate was 83, 
43 and 60 percent. The four-month mortality rate in the present, antigenically 
matched series was 29 percent. The increased survival rate with the selected 
unrelated donor group can be seen in the life-survival curves of FIGURE 4. The 
decrease from the pooled results of the earlier series, however, falls short of 
statistical significance (x2 =2.17, P = 0.14). The increase in survival of the six 
early deaths, from 73 days to 114 days, also falls short of statistical signifi- 
cance (P= 0.14). In view of the limited number of patients, the lack of statisti- 
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cal significance of the improved survival suggested by the life survival curves 
of FIGURE 4 should be interpreted as indicating that the increase in survival 
has not been firmly demonstrated. 
Control of rejection was not difficult in any of these cases. Brief renal shut- 
down during a rejection crisis was observed on two occasions, for one and two 
days, respectively. 
Causes of Death in Unrelated Series 
Four patients died of sepsis: Pneumoncystis carinii pneumonitis and cyto- 
megalic inclusion disease (LD82); viral hepatitis resulting in acute yellow 
atrophy (LD88); pneumonitis and cytomegalic inclusion disease (LD92) and 
systemic histoplasmosis (LD80). The two other patients died as the result of 
technical complications. In one (LD69), the smaller of two renal arteries to 
the homograft was accidentally ligated, resulting in a large renal infarct witi 
hematuria and obstruction of the collecting system by clot. Urinary drainage 
was re-established a t  a second operation but function was poor throughout, 
also partly as the result of an excessive ischemic interval of 51 minutes. He 
died of acute heart failure five days postoperatively. In the other patient 
(LD74), the tail of the pancreas was fractured during removal of a large poly- 
cystic kidney, resulting in a pancreatic fistula. This was ultimately treated 
with resection of the tail of the pancreas but he eventually died 53 days after 
operation of Pseudomonas aeruginosa pneumonitis. 
Pathology of Unrelated Homografts 
Two of these kidneys (LD82 and LD92) showed acute tubular necrosis due 
to hypotension associated with the terminal infection. Margination of lym- 
phoid cells with pyroninophilic cytoplasm in the peritubular capillaries, the 
presence of small groups of similar cells in the edematous interstitiurn, and 
early focal proximal tubular damage was presumed to indicate commencing 
rejection in three of the transplants (LD69, LD74 and LD88). This was ac- 
companied by fibrinoid necrosis of the arteriolar walls in LD74, but in none of 
these cases was renal damage which was due to the homograft reaction a factor 
in the patient's death. Fibrous intimal thickening of the interlobular arteries 
was only found in one homograft (LD80). I t  was not severe and had produced 
little ischemic damage. 
Comparison with the 12 unselected, unmatched kidneys treated in the past 
(TABLE 5) shows that before selection was practiced, obliterative and fibri- 
noid necrotic vascular lesions were more commonly encountered. Fifty-eight 
per cent of the unmatched kidneys showed fibrous intimal thickening of many 
of their interlobular arteries and 42 percent contained fibrinoid necrotic 
arteriolar lesions. In the matched series only 17 percent of the transplants 
were affected by each of these complications. This difference is an indication 
of the frequency with which patients in the first series died while experiencing 
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rejection, and of the infrequency with which this happened in the second 
series. 
Significance of Indiuidu.al Leukocyte Antigens 
The relative significance of individual antigens in histocompatibility is, as 
yet, not apparent from this study. Because many of the deaths were not direct- 
ly attributable to problems in antigenic matching, no pattern of antigenic 
mismatch could be correlated with nonsurvival. The two patients in whom re- 
jection was a contributory factor in death were mismatched in group 1 plus 
the unclassified serum group (LD79) and in groups 3-6,2 and 5 (LD76). Other 
patients mismatched in group 1 or groups 3-6 are currently surviving with 
good function. 
The results in the presently reported series of cases in which donors wer( 
selected on the basis of leukocyte antigen matching are improved compared t. 
those previously obtained in the Denver institutions. The four-month survival 
was considerably better in the patients receiving related homografts, although 
three subsequent deaths reduced the ultimate one year life expectancy to that 
of the original unselected series. However, the average survival time of the 
patients who died during the first year in the selected related group is signifi- 
cantly better than that in the previous series (P = 0.02). In the unrelatea 
group, survival appears to have been very considerably influenced, now ap- 
proaching that obtained in related cases, a result which would have been pre- 
dicted, if the antigen matching had measured histocompatibility factors either 
directly or indirectly. 
As far as can be determined, this improvement did not represent the con- 
tinuation of a trend observed during the treatment of the original 64 non- 
matched cases. The position that improved histocompatibility was a significant 
factor could further be supported by the fact that acute and healed vascular 
lesions in the matched homografts were less frequent than in comparable kid- 
neys from the earlier series. 
Nevertheless, the present study highlights the difficulties that exist in 
attempting to evaluate any human antigen matching technique in the experi- 
mental environment of whole organ transplantation. First, a certain number of 
treatment failures were due either to technical mishaps or to septic complica- 
tions which terminated the patient's life in spite of good homograft function. 
By and large, such cases can not reasonably be said to have presented a fair 
biologic test of the method. Secondly, differences in recipient immunologic re- 
activity vary in the individual uremic patients.8 Thus, an equal mismatch in 
two patients might be manifested as rejections of quite different intensity. 
Third, i t  is impossible to treat each patient in exactly the same way. The toler- 
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ance to azathioprine therapy, and the quantities of steroid doses can not be 
easily standardized, and adjustments in the regimen are often dictated by sub- 
jective clinical judgment. 
Finally, it was impossible to obtain highly desirable matches in every case. 
Even with the best histocompatibility pairs there was a significant number of 
antigenic differences between the donors and recipients, and in some cases 
these were quite high. 
Because of these important reservations, it is essential to refrain from 
overinterpretation of the presently reported data. I t  is conceivable that some 
unrecognized improvement in general management could have occurred, al- 
though the breakdown of past cases into successive thirds did not indicate that 
this was occurring. In other centers, however, a trend of improvement has 
been noted with transplantation of nonmatched cadaveric kidneys.g Whether 
these results can be presumed to indicate that antigenic matching plays a rel- 
atively minor role in renal transplantation with current means of immunosup- 
pression is not yet determined. 
The antigenic matching method described here can not be considered to be 
a definitive method. The use of over 100 antisera to type each patient is 
cumbersome and the exact criteria by which mismatches in groups can be 
shown are as yet uncertain. Although an ever-increasing agreement as to 
leukocyte groups is being obtained by different l a b o r a t ~ r i e s , ~ ' ~ ~  much remains 
to be done in the recognition of definitive leukocyte types. Until these types 
are established with monospecific sera and by thorough genetic studies, the 
matching results must be considered only provisional. The present study, 
however, suggests that even with the current, rather limited knowledge of 
leukocyte groups and the sera available, some measure of assistance may be 
rendered above that of random selection of donors. 
An attempt was made to select donors for human kidney transplantation 
on the basis of lymphocyte antigen matching. Compatibility was assayed by 
reactions of individual antisera on donor and recipient lymphocytes, as well as 
by matching on the basis of the six recognized leukocyte groups. The donor 
judged to be the best match was chosen from pools of related and unrelated 
donors. Although the choice was often limited, a group of donors was selected 
which, as a whole, was slightly more compatible than that achieved by random 
matching. Mismatches which were extremely high or from group 6 were avoided 
whenever possible. 
Eighteen transplants were done from related donors: sixteen of these re- 
cipients lived for a t  least 4 months postoperatively; three more died after 
lo;, 8: and 8 months. Thirteen of the original 18 patients are still alive, 6, 
after 4 to 8 months, four, after 8 to 21 months and three, after more than one 
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year. This represents a slight improvement over the first unmatched Denver 
series treated 2 to 3: years ago. 
Of the 14 recipients in the present series who received kidneys from 
matched unrelated donors, ten lived for more than 4 months; two more died 
after 5 and 10 months respectively. Eight of the original patients are still a- 
live with a minimum follow-up of 6: months; four of these patients are surviv- 
ing 9 to 12 months after operation, and the other three, more than one year. 
These results are improved over that of an original nonselected series of unre- 
lated homotransplants performed in Denver. Furthermore, the survival curve 
in these nonrelated donors and recipients now approximates that which was 
obtained in the past Denver experience with randomly selected related donors. 
Because of the relatively small numbers involved, however, this improvement 
is not statistically significant. 
Pathological studies of the kidneys from the recipients who died were com 
pared to the kidneys of the dead recipients of the first Denver series in which 
donors were randomly selected. Acute vascular lesions which result from se- 
vere rejection were less frequent in this series as compared to the earlier un- 
matched series. 
I t  was concluded that coincidental to matching for provisional leukocyte 
types, an improved early clinical outcome of transplantation was obtained 
with respect to survival and minimization of pathologic changes associated 
with rejection. Whether the improvements are attributable to the matching 
procedure or to other unrecognized factors in the clinical management of the 
patients could not be determined. 
We wish to thank Mr. Edward Victoria, Mr. Charles Eversole and Mr. 
James Tavernakis for their excellent technical assistance. 
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